GHRH 1-29 / Sermorelin

GH Axis

Pulsatile GH release

Reading this compound Reference only

Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.

Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.

Mechanism & Use

Compound type: Peptide
Primary mechanism: GHRH receptor agonism
Primary market use: Hormone optimization

Pharmacology

Molecular weight (Da): 3357.9
Oral bioavailability: N/A
Half-life: ~10-20 min
Route tags: Route-dependent / verify
Evidence level: Approved/compounded
Clinical status: Approved/compounded
Value-for-money score: 5 / 10

Reported protocol signal

SQ: • 300-500 mcg nightly for 30 days (Peptide Therapy), or up to 6 months (World of Peptides)

For orientation only. See disclaimer — always consult a licensed clinician before use.

Notes

Requires ongoing dosing

Sources

https://www.fda.gov/drugs